Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

630

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Oleclumab
DRUG: Monalizumab
DRUG: Dato-DXd
DRUG: AZD0171
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed/Cisplatin
DRUG: Pemetrexed/Carboplatin
DRUG: Carboplatin/Paclitaxel
DRUG: Volrustomig
DRUG: Rilvegostomig

Sponsor

AstraZeneca

Collaborators

[object Object]